Novus Therapeutics, Inc. (24)
Browse by Contract Category
Contracts
-
License Agreement between Lonza Sales AG and Anelixis Therapeutics, LLC, dated September 11, 2018
(Filed With SEC on August 11, 2022)
-
SUBLEASE AGREEMENT BY AND BETWEEN CORPORATE TECHNOLOGIES, INC., SUBLANDLORD AND ELEDON PHARMACEUTICALS, INC., SUBTENANT A PORTION OF 78 Blanchard Road, Burlington, MA 01803...
(Filed With SEC on March 24, 2022)
-
ELEDON PHARMACEUTICALS, INC. Stock Option Agreement Granted Under 2020 Long Term Incentive Plan
(Filed With SEC on March 24, 2022)
-
Series X1 Exchange Agreement, dated January 11, 2022, by and among Eledon Pharmaceuticals, Inc. and the Stockholders named therein
(Filed With SEC on January 13, 2022)
-
Description of Securities
(Filed With SEC on March 31, 2021)
-
Open Market Sales Agreement by and between the Registrant and Jefferies, LLC dated March 30, 2021
(Filed With SEC on March 31, 2021)
-
First Amendment to Restated License Agreement between ALS Therapy Development Foundation, Inc. and Anelixis Therapeutics, Inc. dated September 5, 2020
(Filed With SEC on August 11, 2022)
-
Amended and Restated License Agreement by and between ALS Therapy Development Foundation, Inc. and Anelixis Therapeutics, Inc, dated February 18, 2020
(Filed With SEC on August 11, 2022)
-
SECOND AMENDMENT TO LEASE
(Filed With SEC on March 24, 2022)
-
Executive Employment Agreement, dated September 9, 2020, between Novus Therapeutics, Inc. and David-Alexandre C. Gros, M.D
(Filed With SEC on March 31, 2021)
-
Novus Therapeutics, Inc., 2020 Long Term Incentive Plan
(Filed With SEC on March 31, 2021)
-
Executive Employment Agreement, dated March 15, 2021, between Eledon Pharmaceuticals, Inc. and Paul Little
(Filed With SEC on March 31, 2021)
-
Executive Employment Agreement, dated March 1, 2021, between Eledon Pharmaceuticals, Inc. and Jon Kuwahara
(Filed With SEC on March 31, 2021)
-
Warrant Exchange Agreement, dated December 31, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein
(Filed With SEC on January 7, 2021)
-
Series X Exchange Agreement, dated December 31, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein
(Filed With SEC on January 7, 2021)
-
Description of Securities
(Filed With SEC on March 17, 2020)
-
Exchange Agreement, dated February 13, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein
(Filed With SEC on February 19, 2020)
-
Form of Warrant Exercise Agreement by and between Novus Therapeutics, Inc. and the Holders named therein
(Filed With SEC on January 16, 2020)
-
Form of Private Placement Warrant
(Filed With SEC on January 16, 2020)
-
Management Continuity Agreement, date August 7, 2017, between Novus Therapeutics, Inc. and Catherine C. Turkel
(Filed With SEC on May 14, 2019)
-
Form of Securities Purchase Agreement, dated April 30, 2019, by and between Novus Therapeutics, Inc. and the Purchasers named therein
(Filed With SEC on May 2, 2019)
-
Form of Placement Agent Warrant
(Filed With SEC on May 2, 2019)
-
Form of Warrant
(Filed With SEC on May 2, 2019)
-
Executive Employment Agreement, dated November 10, 2015, between Otic Pharma, Inc. and Catherine C. Turkel
(Filed With SEC on March 28, 2019)